Journals / Molecular Imaging and Radionuclide Therapy / 2021 / Cilt: 30 - Sayı: 3

Prognostic Prediction of BRCA Mutations by 18F-FDG PET/CT SUV maxin Breast Cancer

Meme Kanserlerinde BRCA Mutasyonlarının 18F-FDG PET/BT SUVmax Değeri ile Prognostik Tahmini

Pages
40–50
Publication Date
2022-09-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results of this study showed a strong association between BRCA mutations and SUVmax, which indicates the poor prognosis of BC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aimed to investigate the prognostic prediction of germline BRCA1 and BRCA2 mutations by comparing the maximum standardized uptake value (SUVmax) obtained from 18fluoride-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), which is considered a prognostic factor in breast cancer (BC).
📊
Key Findings & Data:Methods: Retrospective interdisciplinary laboratory results of 92 patients with BC who had germline BRCA1 or BRCA2 mutation profiles and underwent 18F-FDG PET/CT were compared.
💡
Conclusion & Impact:Conclusion: The results of this study showed a strong association between BRCA mutations and SUVmax, which indicates the poor prognosis of BC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aimed to investigate the prognostic prediction of germline BRCA1 and BRCA2 mutations by comparing the maximum standardized uptake value (SUVmax) obtained from 18fluoride-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), which is considered a prognostic factor in breast cancer (BC). Methods: Retrospective interdisciplinary laboratory results of 92 patients with BC who had germline BRCA1 or BRCA2 mutation profiles and underwent 18F-FDG PET/CT were compared. Genotyping was made by next-generation sequencing, and PET/CT scans were re-evaluated. The histopathological data, genetic results, and clinical demographics of all patients were recorded. Patients were divided into two groups in accordance with the presence of germline BRCA1 and/or BRCA2 mutations. Between-group statistical comparison was performed. Results: In PET/CT performed for primary staging, patients with BRCA-positive BC had significantly higher SUVmax (p=0.039), larger tumor size (p=0.025), and presence of axillary nodal metastases (p=0.023) than patients with BRCA-negative BC. Although the Ki-67 index was higher in the BRCA-positive group than BRCA-negative group, this difference was not significant (p=0.157). Moreover, in the BRCA-positive and negative groups, SUVmax, Ki-67 index, and tumor size, grade, and stage were significantly correlated with each other. Conclusion: The results of this study showed a strong association between BRCA mutations and SUVmax, which indicates the poor prognosis of BC.

Özet

Amaç: Bu çalışmanın amacı, meme kanserlerinde (MK) germline BRCA1-BRCA2 mutasyonlarının tahmini prognostik değerini, 18F-florodeoksiglikoz pozitron emisyon tomografi/bilgisayarlı tomografi (18F-FDG PET/BT) tetkikinden elde edilen ve prognostik bir faktör olduğu kabul edilen maksimum standardize tutulum değeri (SUVmaks) ile karşılaştırarak araştırmaktır. Yöntem: Germline BRCA1 veya BRCA2 mutasyon profilleri olan ve 18F-FDG PET/BT taraması yapılan MK’li 92 hastanın retrospektif olarak laboratuvar sonuçları karşılaştırıldı. Genotipleme yeni nesil sıralama tekniği ile yapıldı ve PET/BT taramaları yeniden değerlendirilerek tüm hastaların histopatolojik, genetik sonuçları ve klinik demografik özellikleri not edildi. Hastalar germline BRCA1 ve/veya BRCA2 mutasyonlarının varlığına göre iki gruba ayrıldı ve gruplar arasında istatistiksel karşılaştırma yapıldı. Bulgular: BRCA pozitif MK hastalarının, primer evreleme için yapılan 18F-FDG PET/BT görüntülemesinde, SUVmaks değerleri (p=0,039), tümör boyutu (p=0,025) ve aksiller nodal metastaz varlığı (p=0,023) BRCA negatif MK hastalarından önemli ölçüde daha yüksek bulundu. Ki-67 değeri, BRCA pozitif grupta BRCA negatif gruba göre daha yüksek olmasına rağmen, bu fark istatistiksel olarak anlamlı değildi (p=0,157). Ayrıca BRCA pozitif ve negatif gruplarında; SUVmaks, Ki-67, tümör boyutu, grade ve evre değerlerinin birbirleriyle anlamlı korelasyon gösterdiği bulundu. Sonuç: Mevcut çalışma sonuçlarına göre, BRCA mutasyonları ile SUVmaks değerleri arasında MK için kötü prognozu gösteren güçlü bir ilişki vardır.

🔖

Cite This Article

ÖZDEMİR, S., SILAN, F., ÖZDEMİR, Ö., AKGÜN, M. Y., ARACI, N., ÇIRPAN, İ., ÖZTÜRK, F. K. (2022). Prognostic Prediction of BRCA Mutations by 18F-FDG PET/CT SUV maxin Breast Cancer. Molecular Imaging and Radionuclide Therapy, Cilt: 30 - Sayı: 3, 40–50. https://ajindex.com/articles/425716

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Baglia ML, Cook LS, Mei-Tzu C, Wiggins C, Hill D, Porter P, Li CI. Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer. Int J Cancer 2018;143:1849-1857
  2. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat 2017;165:193-200
  3. De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep 2020;10:7073
  4. Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. JAMA Netw Open 2019;2:e194428
  5. Kim EK, Park SY, Kim SW. Clinicopathological characteristics of BRCAassociated breast cancer in Asian patients. J Pathol Transl Med 2020;54:265-275
  6. Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. Semin Cancer Biol 2018;52:56-73
  7. Huszno J, Kołosza Z, Grzybowska E. BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survival. Oncol Lett 2019;17:1986-1995
  8. Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018;19:169-180. 9. van den Broek AJ, Schmidt MK, van ‘t Veer LJ, Tollenaar RA, van Leeuwen FE. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what’s the evidence? A systematic review with meta-analysis. PLoS One 2015;10:e0120189
  9. Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e4975
  10. Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, Jochelson MS, Gönen M. (18)F-FDG-PET/CT for systemic staging of